| RICHTER, J., A. LUBKING, S. SODERLUND, K. LOTFI, B. MARKEVARN, A. SJALANDER, L. STENKE, S. DENEBERG, E. AHLSTRAND, K. MYHR-ERIKSSON, P. PANAYIOTIDIS, T. GEDDE-DAHL, Daniela ŽÁČKOVÁ, Jiří MAYER, U. OLSSON-STROMBERG, F. X. MAHON, S. SAUSSELE, H. HJORTH-HANSEN and P. KOSKENVESA. Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI. Leukemia. London: Nature Publishing Group, 2021, vol. 35, No 8, p. 2416-2418. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-021-01173-w. |
Other formats:
BibTeX
LaTeX
RIS
@article{1764396,
author = {Richter, J. and Lubking, A. and Soderlund, S. and Lotfi, K. and Markevarn, B. and Sjalander, A. and Stenke, L. and Deneberg, S. and Ahlstrand, E. and MyhrandEriksson, K. and Panayiotidis, P. and GeddeandDahl, T. and Žáčková, Daniela and Mayer, Jiří and OlssonandStromberg, U. and Mahon, F. X. and Saussele, S. and HjorthandHansen, H. and Koskenvesa, P.},
article_location = {London},
article_number = {8},
doi = {http://dx.doi.org/10.1038/s41375-021-01173-w},
keywords = {TKI discontinuation; CML; MMR-final report; AFTER-SKI},
language = {eng},
issn = {0887-6924},
journal = {Leukemia},
title = {Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI},
url = {https://www.nature.com/articles/s41375-021-01173-w.pdf},
volume = {35},
year = {2021}
}
TY - JOUR
ID - 1764396
AU - Richter, J. - Lubking, A. - Soderlund, S. - Lotfi, K. - Markevarn, B. - Sjalander, A. - Stenke, L. - Deneberg, S. - Ahlstrand, E. - Myhr-Eriksson, K. - Panayiotidis, P. - Gedde-Dahl, T. - Žáčková, Daniela - Mayer, Jiří - Olsson-Stromberg, U. - Mahon, F. X. - Saussele, S. - Hjorth-Hansen, H. - Koskenvesa, P.
PY - 2021
TI - Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI
JF - Leukemia
VL - 35
IS - 8
SP - 2416-2418
EP - 2416-2418
PB - Nature Publishing Group
SN - 08876924
KW - TKI discontinuation
KW - CML
KW - MMR-final report
KW - AFTER-SKI
UR - https://www.nature.com/articles/s41375-021-01173-w.pdf
N2 - Discontinuation of tyrosine kinase inhibitor (TKI) treatment for chronic phase (CP) CML patients with a deep molecular response (DMR) has entered standard practice. This is based on numerous clinical studies showing that ~50% of patients with DMR can stop TKI treatment without imminent disease relapse. However, in most of these trials long-term follow-up has been limited.
ER -
RICHTER, J., A. LUBKING, S. SODERLUND, K. LOTFI, B. MARKEVARN, A. SJALANDER, L. STENKE, S. DENEBERG, E. AHLSTRAND, K. MYHR-ERIKSSON, P. PANAYIOTIDIS, T. GEDDE-DAHL, Daniela ŽÁČKOVÁ, Jiří MAYER, U. OLSSON-STROMBERG, F. X. MAHON, S. SAUSSELE, H. HJORTH-HANSEN and P. KOSKENVESA. Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI. \textit{Leukemia}. London: Nature Publishing Group, 2021, vol.~35, No~8, p.~2416-2418. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/s41375-021-01173-w.
|
